T
TG Therapeutics D
D
TGTX
33.310
USD
-0.16
(-0.48%)
مغلق
حجم التداول
35,421
الربح لكل سهم
1
العائد الربحي
-
P/E
88
حجم السوق
5,285,151,569
الأخبار المقالات
العنوان: TG Therapeutics
القطاع: Healthcare
الصناعة: Biotechnology
TG Therapeutics Inc is a fully integrated, commercial-stage, biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell diseases. The company has received approval from the U.S. Food and Drug Administration (FDA) for BRIUMVI (ublituximab-xiiy) for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS). In addition, it is developing TG-1701 (BTK inhibitor), Azer-Cel (allogeneic CD19 CAR T),and TG-1801 (anti-CD47/CD19 bispecific mAb) for B-cell disorders, which are under Phase 1 trials. Geographically, the company generates a majority of its revenue selling BRIUMVI in the United States, with the rest coming from sales in other countries.